{"schema_version":"1.0","type":"article","title":"減肥藥還是太強了，禮來 猛健樂 賺爛！","url":"https://drugnews.com.tw/articles/2026-05-08-lilly-tirzepatide-glp1-growth.html","markdown_url":"https://drugnews.com.tw/articles/2026-05-08-lilly-tirzepatide-glp1-growth.md","lang":"zh-Hant","date":"2026-05-08","publish_at":"2026-05-08T10:30:00+08:00","updated_at":"2026-05-08","category":"商業分析系列","topic":"商業分析系列","tags":["Dcard","免費文章","CAR-T","Kelonia","GLP-1","Tirzepatide","ADC","CNS"],"summary":"2026 年第一季，Eli Lilly 交出了一份讓整個製藥業都很難忽視的成績單：單季總營收 197.99 億美元，年增 56%；調整後 EPS 達 8.55 美元，大幅優於市場預期。真正撐起這份財報的，仍然是那個已經把全球代謝藥市場打穿的名字：tirzepatide。","key_points":[],"facts":[],"sections":["01｜GLP-1 的量價關係：禮來真正厲害的，不是漲價，而是降價後還能成長","02｜Mounjaro 與 Zepbound 是兩個不同故事：一個有保險，一個還在打支付戰","03｜GLP-1 滲透率遠未到頂：禮來真正要打的，是那 90% 還沒進場的人","04｜現金太多怎麼辦？禮來開始用 GLP-1 的錢買下一個十年","05｜Ventyx：從肥胖走向發炎，GLP-1 之後是代謝－免疫閉環","06｜Centessa：從體重進入睡眠，代謝巨頭開始碰 CNS","07｜Orna + Kelonia：in vivo CAR-T 兩條路線都要，禮來不做選擇題","08｜CrossBridge 與 Ajax：在腫瘤裡買下一代抗藥性解法","09｜禮來的併購哲學：不是 FIC 崇拜，而是 BIC 反超","10｜台灣「減重藥概念股」"],"references":[{"title":"[0]: 各公司官網＆公開資料","source":"","date":"","url":""},{"title":"[1]:","source":"","date":"","url":""},{"title":"Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines","source":"","date":"","url":""},{"title":"Revenue in Q1 2026 increased 56% to $19.8 billion primarily driven by volume growth, partially offset by lower realized prices from Mounjaro and Zepbound. Q1...","source":"","date":"","url":""},{"title":"www.prnewswire.com","source":"","date":"","url":""},{"title":"[2]:","source":"","date":"","url":""},{"title":"marketwatch.com","source":"","date":"","url":""},{"title":"https://www.marketwatch.com/story/lillys-stock-rallies-as-sales-of-glp-1-drugs-nearly-double-09c01977","source":"","date":"","url":"https://www.marketwatch.com/story/lillys-stock-rallies-as-sales-of-glp-1-drugs-nearly-double-09c01977"},{"title":"www.marketwatch.com","source":"","date":"","url":""},{"title":"[3]:","source":"","date":"","url":""},{"title":"Medicare GLP-1 Bridge","source":"CMS","date":"","url":""},{"title":"Centers for Medicare & Medicaid Services (CMS) announced the Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth (BALANCE) Model and a separate short-term demonstration (now called the “Medicare GLP-1 Bridge”","source":"","date":"","url":""},{"title":"www.cms.gov","source":"","date":"","url":""},{"title":"[4]:","source":"","date":"","url":""},{"title":"BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model","source":"CMS","date":"","url":""},{"title":"The BALANCE Model aims to increase access to select GLP-1 medications and healthy lifestyle interventions — to help people with Medicare and Medicaid improve their health.","source":"","date":"","url":""},{"title":"www.cms.gov","source":"","date":"","url":""},{"title":"[5]:","source":"","date":"","url":""},{"title":"The top 20 pharma companies by 2025 revenue","source":"Fierce Pharma","date":"","url":""},{"title":"Boosted by a 45% increase in sales in 2025, Eli Lilly has jumped six notches in the annual top-20 revenue ranking, becoming the third-largest company in the biopharma industry.","source":"","date":"","url":""},{"title":"www.fiercepharma.com","source":"","date":"","url":""},{"title":"[6]:","source":"","date":"","url":""},{"title":"[7]:","source":"","date":"","url":""},{"title":"Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders","source":"","date":"","url":""},{"title":"/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage company developing a new class of medicines...","source":"","date":"","url":""},{"title":"www.prnewswire.com","source":"","date":"","url":""}],"images":[{"alt":"Dcard 原圖：減肥藥還是太強了，禮來 猛健樂 賺爛！","url":"https://drugnews.com.tw/assets/articles/lilly-tirzepatide-glp1-growth/dcard-01.webp"},{"alt":"Dcard 原圖：減肥藥還是太強了，禮來 猛健樂 賺爛！","url":"https://drugnews.com.tw/assets/articles/lilly-tirzepatide-glp1-growth/dcard-02.png"},{"alt":"Dcard 原圖：減肥藥還是太強了，禮來 猛健樂 賺爛！","url":"https://drugnews.com.tw/assets/articles/lilly-tirzepatide-glp1-growth/dcard-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/lilly-tirzepatide-glp1-growth/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-05-08）。減肥藥還是太強了，禮來 猛健樂 賺爛！。https://drugnews.com.tw/articles/2026-05-08-lilly-tirzepatide-glp1-growth.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-05-08-lilly-tirzepatide-glp1-growth-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}